Nexalin Technology, Inc. announced on February 3, 2025, the publication of a landmark study in the Journal of Affective Disorders. The research demonstrated the potential efficacy of its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology in delivering meaningful reductions in systolic and diastolic blood pressure in patients with major depressive disorder (MDD).
The study analyzed data from a randomized controlled trial involving 68 first-episode, drug-naive MDD patients. Participants underwent 20 sessions of either active DIFS or sham stimulation over four weeks, targeting brain regions associated with blood pressure regulation.
Significant reductions in blood pressure were observed as early as the fourth week of treatment, with greater reductions among participants who had higher baseline blood pressure. This finding expands the potential applications of DIFS technology beyond mental health to systemic wellness, such as improving cardiovascular health, and complements prior research on depression, insomnia, PTSD, and Alzheimer’s disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.